HumacyteHUMA
HUMA
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
33% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 39
13% more funds holding
Funds holding: 143 [Q3] → 162 (+19) [Q4]
9% more capital invested
Capital invested by funds: $195M [Q3] → $213M (+$17.7M) [Q4]
2.72% more ownership
Funds ownership: 29.99% [Q3] → 32.71% (+2.72%) [Q4]
44% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $7.9M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
907%
upside
Avg. target
$20
1,242%
upside
High target
$25
1,578%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 30% 1-year accuracy 98 / 328 met price target | 1,578%upside $25 | Buy Maintained | 31 Mar 2025 |
HC Wainwright & Co. Vernon Bernardino 15% 1-year accuracy 10 / 67 met price target | 907%upside $15 | Buy Reiterated | 12 Mar 2025 |
Financial journalist opinion
Based on 12 articles about HUMA published over the past 30 days
Neutral
Seeking Alpha
4 days ago
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Josh Jennings - TD Cowen & Company Ryan Zimmerman - BTIG Vernon Bernardino - H.C. Wainwright Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen.
Neutral
GlobeNewsWire
4 days ago
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -
Negative
Zacks Investment Research
6 days ago
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Neutral
GlobeNewsWire
6 days ago
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025.
Neutral
GlobeNewsWire
1 week ago
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about March 27, 2025, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,750,000 shares of Humacyte's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
Neutral
GlobeNewsWire
1 week ago
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares are being offered by Humacyte.
Positive
Zacks Investment Research
1 week ago
Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $3.32, denoting no change from the preceding trading day.
Neutral
GlobeNewsWire
3 weeks ago
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
Positive
Zacks Investment Research
3 weeks ago
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Neutral
Business Wire
3 weeks ago
Trestle Bio Announces Research Collaboration with Humacyte
SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical stage company developing bioengineered kidney tissues for patients suffering from end stage renal disease (ESRD). The collaboration will explore technology synergies for bioengineering vascularized or.
Charts implemented using Lightweight Charts™